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The centromedial amygdala (CeM), a subdivision of
the central amygdala (CeA), is believed to be the
main output station of the amygdala for fear expres-
sion. We provide evidence that the Tac2 gene, ex-
pressed by neurons specifically within the CeM, is
required for modulating fear memories. Tac2 is colo-
calized with GAD65 and CaMKIIa but not with PKCd
and Enk neurons in the CeM. Moreover, the Tac2
product, NkB, and its specific receptor, Nk3R, are
also involved in the consolidation of fear memories.
IncreasedTac2expression, throughastress-induced
PTSD-like model, or following lentiviral CeA overex-
pression, are sufficient toenhance fear consolidation.
This effect is blocked by the Nk3R antagonist osane-
tant. Concordantly, silencing of Tac2-expressing
neurons in CeA with DREADDs impairs fear consoli-
dation. Together, these studies further our under-
standing of the role of the Tac2 gene and CeM in
fear processing and may provide approaches to
intervention for fear-related disorders.
INTRODUCTION
Among learning and memory processes, fear memories are
crucial in anxiety disorders such as panic disorder, phobia,
and posttraumatic stress disorder (PTSD). PTSD occurs in
some individuals after experiencing or witnessing extreme trau-
matic events. The symptoms of PTSD include re-experiencing
memories of these traumatic events through intrusive thoughts,
flashbacks, and nightmares (American Psychiatric Association,
2013). PTSD is also generally accompanied by hyperarousal
symptoms. Moreover, persistent highly aversive memories
related to the trauma, potentially overconsolidated memories,
and the inability of these memories to be extinguished are all
frequent characteristics of this disorder. Specifically relevant is
the memory consolidation phase following emotional learning,
since it is required to stabilize the initial fear memory trace.
In order to decrease the prevalence of PTSD, it is necessary to
identify biological and environmental risk and resilience markers
(Norrholm and Ressler, 2009; Vermetten and Lanius, 2012), to444 Neuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc.find early interventions after trauma exposure (Kearns et al.,
2012), and to treat the disorder when it is present and debilitating
(Andero and Ressler, 2012; Hetrick et al., 2010). Notably, under-
standing molecular pathways mediating the initial fear consoli-
dation event is particularly important to target the prevention of
PTSD. The only FDA-approved pharmaceutical treatments for
PTSD are selective serotonin reuptake inhibitor (SSRI) antide-
pressants, which have met with limited results in clinical trials
(Hetrick et al., 2010). Even when antidepressants are combined
with exposure-based psychotherapy, increased effectiveness
has not always been demonstrated (Hetrick et al., 2010). Thus,
more effective, targeted approaches to prevention and treat-
ment are needed to normalize the functioning of areas key to
fear processes such as the amygdala, the hippocampus, or the
medial prefrontal cortex (mPFC).
The tachykinins refer to two peptides encoded in rodents by
the Tachykinin 1 (Tac1) and Tac2 (TAC3 in humans) genes, which
are involved in neurotransmission and neuromodulation in the
CNS (Beaujouan et al., 2004). Tac1 encodes a precursor protein
that produces two peptides, substance P (SP) and neurokinin A
(NkA), whereas Tac2/TAC3 encodes neurokinin B (NkB). SP and
NkA have been previously implicated in fear processes and
PTSD (Dunlop et al., 2012). Unfortunately, clinical trials with
pharmaceutical agents targeting the Tac1 pathway have not pre-
viously shown beneficial effects in PTSD treatment (Dunlop et al.,
2012). A possible explanation for this lack of effect is that the SP
and NkA receptors (Neurokinin 1 receptor [Nk1R] and Neurokinin
2 receptor [Nk2R]) are widely expressed in the brain. So, when
administering drugs that specifically target Nk1 and Nk2, they
interact with multiple brain regions affecting multiple functions
(Beaujouan et al., 2004). In contrast, the expression of Tac2,
NkB, and its specific receptor, Neurokinin 3 receptor (Nk3R),
are relatively restricted in rodents to brain regions that regulate
emotion, such as the amygdala (Beaujouan et al., 2004; Duarte
et al., 2006). Nk3R is a G protein-coupled tachykinin receptor
that binds NkB with highest affinity (Gether, 2000; Khawaja
and Rogers, 1996). Nk3R couples to the pertussis toxin-insensi-
tive G proteins Gq/G11, the activation of which results in the
production of inositol triphosphate and diacylglycerol and the
activation of protein kinase C (Khawaja and Rogers, 1996). Addi-
tionally, it has been shown that TAC3 and Nk3R are expressed in
the equivalent areas in rhesus monkeys and humans (Mileusnic
et al., 1999; Nagano et al., 2006).
Here, beginning with an unbiased discovery approach, we
show that the Tac2 gene is dynamically regulated during the
Figure 1. Differential Regulation of Tac2
Gene Expression in the Amygdala during
Cued-Fear Conditioning
(A) With average linkage hierarchical clustering of
an RNA microarray, there is a differential gene
regulation 30 min and 2 hr after auditory fear
conditioning (FC) when compared to home cage
group (no FC). n = 4 per group.
(B) Tac2 mRNA levels are rapidly upregulated in
the amygdala during fear consolidation 30 min
after fear conditioning. *p % 0.05 versus HC and
2 hr. n = 7–8 per group.
(C) Tac2 upregulation occurs when the condi-
tioned stimulus (acoustic tone) and the uncondi-
tioned stimulus (electric footshock) are paired but
not when they are unpaired. *p% 0.05 versus HC
and unpaired. n = 11–15 per group. Mean + SEM
is shown.
(D) Tac2 expression by radioactive in situ hybrid-
ization in the amygdala is restricted to the central
amygdala (CeA) with highest expression in the
CeM amygdala. Scale bar, 1 mm. See also Fig-
ure S1 and Tables S1 and S2.
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(CeA). Additionally, Nk3R activation is required for normal
consolidation of fear memory formation in mice. Furthermore,
increased expression of the Tac2 gene, NkB peptide, and acti-
vation of Nk3R may be involved in stress sensitization and
overconsolidation of fear. In contrast, genetic silencing of
Tac2-expressing neurons impairs fear consolidation. Blockade
of this pathway may provide for a novel therapeutic approach
for disorders with altered fear learning such as PTSD.
RESULTS
Tac2 Is Involved in Fear Learning
Using amygdala tissue punches from mice that had been sacri-
ficed 30 min or 2 hr after auditory fear conditioning (FC) (CS,
acoustic tone; US, electric footshocks; Figure S1A available on-
line), we performed an mRNAmicroarray. Using average linkage
hierarchical clustering, the microarray heat map shows differen-
tial gene regulation at 30 min and at 2 hr after fear learning,
which is a critical period for consolidation of fear memories (Re-
ssler et al., 2002; Figure 1A). False discovery rate (FDR) wasNeuron 83, 444–4calculated with SAM 4.01 using a stan-
dard 5% cutoff criteria. The cutoff criteria
was set with an FDR at the 1.3-fold level
for the 2 hr after fear conditioning (FC)
group, since with the more conservative
1.5-fold cutoff used in the 30 min after
FC group, no genes were initially identi-
fied. The criteria followed in Tables S1
and S2 for a Yes in the column ‘‘Specif-
ically highly expressed in the amygdala’’
is the following: (1) very high expression
in the amygdala (red color, Allen Brain
Atlas), and (2) no expression of the
gene in the hippocampus or PFC (otherkey areas related to emotional learning). Moreover, from the
top candidates of this microarray, the only gene that is specif-
ically highly expressed in the amygdala and belongs to a ‘‘drug-
gable’’ pathway with available agonists and antagonists that
cross the blood-brain barrier and can be used systemically is
Tac2 (see Tables S1 and S2; Figures S1B and S2). Therefore,
we focused on understanding and manipulating the Tac2
pathway.
Independent replication studies with additional fear-condi-
tioned mice show that Tac2 is rapidly upregulated at 30 min after
FC, returning to basal levels at 2 hr (ANOVA F3,28 = 5.014, p %
0.01, post hoc *p % 0.05 versus home cage [HC] and 2 hr;
Figure 1B). Moreover, in an additional replication, Tac2 mRNA
upregulation only occurred when the conditioned and uncondi-
tioned stimuli are paired but not when they are unpaired, sug-
gesting that within this paradigm, Tac2-increased expression
is specific to associative cued fear learning and independent of
nonspecific stress and/or contextual learning (ANOVA F2,36 =
3.93, p % 0.05, post hoc *p % 0.05 versus HC and unpaired;
Figure 1C). See Figure S3 for detailed interactions of the Tac2
gene and Nk3R.54, July 16, 2014 ª2014 Elsevier Inc. 445
Figure 2. Tac2 Is Colocalized with Gluta-
mate Decarboxylase 65 and Calmodulin-
Dependent Protein Kinase II a but Is Not
Colocalized with Protein Kinase C Delta or
Enkephalin-Expressing Neurons in the CeM
(A) Tac2mRNA expression in the CeA and BLA by
nonradioactive fluorescent in situ hybridization
(FISH). Scale bar, 100 mm.
(B) Tac2 mRNA expression by FISH in another
coronal section. Scale bar, 100 mm.
(C) PKCd mRNA expression by FISH. Scale bar,
100 mm.
(D) Enk mRNA expression by FISH. Scale bar,
100 mm.
(E) Right: (A) and (C) merged showing different
pattern of expression of Tac2 and PKCd in the
CeA. Scale bar, 100 mm. Left: confocal image
showing no colocalization of Tac2 and PKCd in the
CeM. Scale bar, 15 mm.
(F) Right: (B) and (D) merged showing different
pattern of expression of Tac2 and Enk. Scale bar,
100 mm. Left: confocal image showing no coloc-
alization of Tac2 and Enk in the CeM. Scale bar,
15 mm.
(G) Confocal image showing colocalization of Tac2
mRNA expression and GAD65 peptide in the CeM.
Scale bar, 15 mm.
(H) Confocal image showing colocalization of Tac2
mRNA expression and CaMKIIa peptide in the
CeM. Scale bar, 15 mm. CeM, centromedial
amygdala; CeL, centrolateral amygdala; CeC,
centrocentral amygdala; CeA, central amygdala;
BLA, basolateral amygdala.
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Figures 1D and S1B show a radioactive in situ hybridization
demonstrating that the areas where Tac2 gene is expressed
are quite specific and limited within in the mouse brain: bed
nucleus of the stria terminalis, hypothalamus, habenula, central
amygdala (CeA), zona incerta, and medial mammillary nucleus.
Tac2 is highly expressed in the CeA within the amygdala, with
no expression in the basolateral amygdala (BLA) or lateral
amygdala (LA) (Figure 1D). The highest expression of Tac2
within the CeA occurs in the medial subdivision of the central
amygdaloid nucleus (CeM), whereas lower expression is
observed in the centrolateral (CeL) and centrocentral (CeC)
amygdala.446 Neuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc.Recently, specific cell populations
within the central nucleus have received
attention for distinct roles in fear learning.
For example, PKCd has been suggested
to be part of a microcircuit in which the
CeL amygdala neurons inhibit neuronal
output to the CeM during the conditioned
stimulus, which drives fear expression,
called CeLoff units (Haubensak et al.,
2010). Moreover, around 40% of protein
kinase C delta (PKCd)-expressing neu-
rons also express Enkephalin (Enk) in the
CeL (Haubensak et al., 2010). Of note,Enk mRNA levels are increased after FC in the CeL (Petrovich
et al., 2000). Since other neuronal populations have been previ-
ously related to fear processes in the CeA, wewished to examine
whether Tac2 mRNA colocalized with them, suggesting func-
tional interactions. Using double fluorescent in situ hybridization
(FISH), we show that Tac2 gene expression ismostly not colocal-
ized with PKCd or Enk and is expressed primarily within the CeM
(Figures 2A–2F). Thus, given the lack of colocalization and
regional and functional specificity of these cell populations, we
have uncovered a subdivision-specific cell population that may
be involved in the consolidation of fear memory. Additionally,
the colocalization of Tac2 mRNA levels and the 65 kDa isoform
of glutamic acid decarboxylase (GAD65) peptide in the CeM
Figure 3. Fear Conditioning, Expression of Neurokinin B and Neuro-
kinin 3 Receptor in the Amygdala
(A) The Tac2 product Neurokinin B (NkB) is detected by immunocytochemistry
in mouse amygdala cell culture. NkB is highly expressed in the soma and in the
dendrites. Red represents NkB signal. Blue represents neuronal nucleus,
NeuN. Scale bar, 25 mm.
(B) Immunohistochemistry studies show high expression of NkB in the central
amygdala (CeA). Scale bar, 125 mm.
(C) NkB is upregulated at 2 hr in the amygdala after fear conditioning. **p %
0.01 versus home cage, n = 6–8 per group.
(D) Amygdala cell culture with osanetant, a potent and specific neurokinin 3
receptor (Nk3R) antagonist. Incubation with 20 mg and 40 mg of osanetant
enhances Nk3R mRNA levels. This suggests that osanetant activates Nk3R
and its downstream signaling in the amygdala. *p % 0.05 versus Veh, **p %
0.01 versus Veh, n = 2 per group. Mean + SEM is shown.
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gamma-aminobutyric acid (GABA) in fear learning. Calmodulin-
Dependent Protein Kinase II a (CaMKIIa), a well-characterized
neuronal population involved in synaptic plasticity, is also colo-
calized with Tac2 mRNA in the CeM (Figure 2H). Interestingly,
GAD65 and CaMKII are associated with the consolidation of
fear memories in the amygdala, although little is known about
the specific role of these peptides in each substructure (Ber-
gado-Acosta et al., 2008; Lepicard et al., 2006).
We also examined detection of the NkB peptide in amygdala
cell culture, demonstrating that the peptide is highly present in
both soma of neurons and dendrites (Figure 3A). Moreover,
NkB peptide is also highly expressed in the CeA (Figure 3B).
Interestingly, NkB is upregulated in the amygdala 2 hr after FC(Student’s t test, t = 2.902, **p% 0.01 fear conditioning versus
home cage; Figure 3C). The Nk3R antagonist osanetant has
already been used in humans in clinical trials for schizophrenia.
Although it appears to have no beneficial effects in the treatment
of schizophrenia, these studies show that it is well tolerated and
safe in humans (Meltzer et al., 2004). Here, in amygdala cell
culture, osanetant inactivates the Nk3R and leads to a compen-
satory increase in Nk3R expression as suggested by dose-
dependent enhanced Nk3R mRNA levels (ANOVA F3,5 =
10.014, p % 0.05; post hoc *p % 0.05 versus Vehicle (Veh),
**p% 0.01 versus Veh; Figure 3D).
Osanetant and Emotional Learning
The above studies suggest that osanetant may be an ideal can-
didate to target the Nk3R in the amygdala in vivo, and we wished
to examine its effects behaviorally. Osanetant given sys-
temically, 30 min before open-field, elevated plus maze, and
the conditioning chamber elicits no changes in anxiety-like
behavior, locomotor activity, or electric shock reactivity (Fig-
ure S4). Notably, when osanetant is dosed from 30 min before
auditory FC up to 1 hr after training, it does not affect fear acqui-
sition but impairs fear memory consolidation as shown by
decreased freezing in the fear expression test (Figures 4A and
S4G; Student’s t test, 30 min, t = 3.042; 10 min after FC, t =
2.277; 1 hr after FC, t = 2.872; *p% 0.05 versus vehicle).
Recently, the PACAP-PAC1R pathway has been associated
with PTSD in humans as well as in animal models (Ressler
et al., 2011; Stevens et al., 2014). These prior data showed
that expression of theADCYAP1R1 gene (encoding the PAC1 re-
ceptor) is increased following FC. Here we found that osanetant
given before FC also normalizes the levels of ADCYAP1R1
mRNA levels in the amygdala (ANOVA F2,31 = 5.541, p % 0.01;
post hoc *p% 0.05 versus Veh-FC; **p% 0.01 versus Veh-FC;
Figure 4B). These data suggest that inhibition of the Tac2/
NKB/Nk3R pathway may prevent activation of a stress-related
gene pathway previously associated with PTSD. Concordantly,
bilateral infusion of osanetant in the CeA also impairs fear mem-
ory consolidation, suggesting that CeA-NK3R are required for
the formation for emotional memories (Student’s t test; t =
2.268, *p% 0.05 versus vehicle; Figures 4C and 4D).
We have shown in previous studies that mice exposed for 2 hr
to a severe one-time stressor, immobilization to a wooden board
(IMO), present long-term PTSD-like symptoms: impaired fear
extinction and spatial memory and enhanced anxiety-like behav-
iors (Andero et al., 2011, 2013). Additionally, IMO in rats elicits
alterations of the hypothalamic-pituitary-adrenal (HPA) axis
that may be similar to the process initiating PTSD in humans
(Armario et al., 2008). Notably, Tac2 mRNA levels were more
robustly upregulated in IMO-treatedmice than in naivemice after
FC, consistent with enhanced Tac2-dependent fear processing
(ANOVA F3,53 = 6.242, p % 0.001, post hoc *p % 0.05 versus
HC, **p % 0.01 versus IMO; Figure 4F). Additionally, osanetant
given systemically after FC impaired memory consolidation in
IMO-treated mice, as shown by decreased freezing in the fear
expression test (ANOVA repeated-measures, F1,13 = 6.072,
*p % 0.05; Figure 4G). This suggests that Nk3R antagonism
reduces enhanced fear memory consolidation in a PTSD-like
model.Neuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc. 447
Figure 4. An Nk3R Antagonist Impairs
Cued-Fear Memory Consolidation when
Infused Systemically in the Central Amyg-
dala and in a PTSD-like Mouse Model
(A) Osanetant impairs cued-fear memory when
given from 30 min to up to 1 hr after fear acquisi-
tion. The figure shows the time spent in freezing
behavior during the fear expression test when the
CS is presented. *p % 0.05 versus Veh. n = 4–12
per group.
(B) Osanetant given intraperitoneally 30min before
fear conditioning impaired the enhancement of
mRNA levels of the Pac1 receptor (Adcyap1r1),
*p% 0.05 versus Veh-FC; **p% 0.01 versus Veh-
FC. n = 9–12 per group. The PACAP-PAC1R
pathway is associated with PTSD, fear condition-
ing, and stress.
(C) Osanetant bilaterally injected into the central
amygdala immediately after fear conditioning
causes impaired fear memory consolidation as
shown by lower freezing in the cued-fear expres-
sion test *p% 0.05, n = 3–9 mice per group.
(D) Histological verification of osanetant infusion
sites. Left: toluidine blue staining showing an
example of the tip of the cannula in the CeA. Scale
bar, 250 mm. Right: the dots indicate the lowest
point of the injector tip.
(E) Timeline of the experiment.
(F) Cued-fear conditioning enhances Tac2 levels
30 min after fear conditioning in naive mice but
more robustly in mice with a previous exposure to
immobilization to a wooden board (IMO), a PTSD-
like model. n = 12–15 per group. *p% 0.05 versus
HC, **p% 0.01 versus IMO.
(G) Osanetant was given immediately after FC and
impaired fear memory consolidation in mice that
had been previously exposed to a traumatic stress
as shown by reduced freezing in the fear expres-
sion test, *p% 0.05. n = 8 per group. Mean + or ±
SEM is shown. Veh, vehicle; Osa, osanetant.
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We next developed a viral vector to overexpress the Tac2 gene
in an inducible fashion within the brain, the lentivirus-Tac2 (LV-
Tac2). We first tested its functional expression by infecting
HEK293 cells with the LV-Tac2 compared to control LV-GFP
lentiviruses, demonstrating that theNkBpeptidewas robustly ex-
pressed (Figures5Aand5B).We thenexamined thebehavioral ef-
fects of Tac2 overexpression in mice. LV-Tac2 or LV-GFP were
bilaterally infused in theCeA (Figures 5Cand5D)and14days later
Tac2 was found to be overexpressed by 42%, as determined by
mRNA levelswith in situ hybridization, compared tomice that had
receivedLV-GFP (Student’s t test; t =3.841, ***p%0.001versus
LV-GFP; Figure 5E). Mice infected with the LV-Tac2 or LV-GFP
received systemic osanetant or vehicle immediately after FC,
and then fear expression was tested 24 hr later. Specific CeA-
Tac2 overexpression elicited a significant enhancement of fear
memory consolidation (ANOVA F3,20 = 8.512, p % 0.05; post448 Neuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc.hoc **p% 0.01 versus LV-GFP-Veh; Fig-
ure 5H, right). Interestingly, we found
that Tac2 overexpression in the CeA didnot induce changes in anxiety-like behavior or fear acquisition
(Figures 5G and 5H). Replicating our previous findings, osanetant
impaired fear memory consolidation when given to mice with
the control LV-GFP (post hoc, *p % 0.05 versus LV-GFP-Veh;
Figure 5H, right). Additionally, the enhanced fear memory
consolidation causedbyCeA-Tac2overexpressionwas reversed
by osanetant (post hoc, **p % 0.01 versus LV-Tac2-Osa and
LV-GFP-Osa; Figure 5H, right). See Figure S5 for a graphical
representation of the Tac2-LV overexpression.
Silencing of Tac2-Expressing Cells and Emotional
Learning
To further understand the role of the Tac2 gene, we temporarily
silenced the activity of neurons expressing this gene in the CeA
during fear learning using designer receptors exclusively acti-
vated by designer drugs (DREADD) technology. The B6.129-
Tac2tm1.1(cre)Qima/J (Tac2-Cre) (Mar et al., 2012) mice were
Neuron
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double-floxed hM4D-mCherry virus (hM4Di-mCherry AAV) (Fig-
ure 6A). This elicited specific expression of the mCherry reporter
in Tac2 cells within the CeA, but not any other area of the brain,
suggesting the insertion of the DREADD receptor on the plasma
membrane (Figures 6B and 6C; Krashes et al., 2011). Fourteen
days later, clozapine-N-oxide (CNO), which binds to the inserted
receptor but otherwise is pharmacologically inert, was given
systemically 30 min before FC in both groups, Tac2-Cre-/
hM4Di-mCherry and Tac2-Cre+/hM4Di-mCherry. CNO had no
effect on fear acquisition as shown by equivalent amount of
freezing in both groups (Figure 6D). However, when animals
were tested for fear expression, 24 hr later in the absence of
CNO, the Tac2-Cre+/hM4Di-mCherry mice presented less
freezing, suggesting impaired fear memory consolidation (Stu-
dent’s t test, t = 3.257, *p % 0.05 Tac2-Cre-/hM4Di-mCherry
versus Tac2-Cre+/hM4Di-mCherry; Figure 6D). This demon-
strates that the animals expressing Tac2-Cre+/hM4Di-mCherry
and inducible Gi to temporally silence the activity of Tac2-ex-
pressing neurons exhibit significantly less fear consolidation
when tested for fear learning. Mice were then retrained with a
different CS and a different context in the same FC apparatus,
as in previous experiments but without dosing CNO. Tac2-
Cre-/hM4Di-mCherry and Tac2-Cre+/hM4Di-mCherry mice
showed similar amount of freezing in the FC and fear expression
test (Figure 6E). This suggests that when Tac2-expressing neu-
rons are not silenced, there is normal fear memory consolidation
in both Tac2-Cre-/hM4Di-mCherry and Tac2-Cre+/hM4Di-
mCherry groups. Moreover, when given CNO, these two groups
presented equivalent levels of anxiety-like behavior and pain
sensitivity (Figure 6F and Figure S6).
DISCUSSION
Previous reports have shown that Nk3R is associated with
memory processes in hippocampus-dependent tasks in rodents
(de Souza Silva et al., 2013; Siuciak et al., 2007; Zlomuzica et al.,
2008). Here, we provide evidence that Tac2-NkB-Nk3R signaling
within the CeA is required for the modulation of fear memory
consolidation. Other studies have shown that the CeA is required
for the acquisition, consolidation, and expression of fear mem-
ories (Wilensky et al., 2006). Here we show mechanisms that
may also be involved in those processes within the CeA. To
the best of our knowledge, this is the first evidence that a
neuronal population specifically highly expressed in the CeM,
Tac2 and its product NkB peptide, are required for the modula-
tion of fear memory consolidation affecting neither uncondi-
tioned fear nor anxiety-like behavior. All that is known about
NkB release is from in vitro experiments, where it is suggested
that NkB release is potassium evoked and calcium dependent,
fulfilling the criterion of a neurotransmitter or a neuromodulator
(Lindefors et al., 1985). More studies about this topic would be
desirable to further understand the mechanisms of the Tac2/
NkB/Nk3R pathway.
Our findings also suggest that CeA-Tac2 lentiviral overexpres-
sion enhances fear memory consolidation but Nk3R antagonism
prevents it. This shows that Nk3R antagonism within the CeA is
able to normalize dysregulated functioning induced by the Tac2gene. We believe that it is possible that osanetant given system-
ically or intracranially within the CeAmay be acting in the Nk3R in
all areas of CeA and not only in the CeM (Smith and Flynn, 2000;
Yip andChahl, 1997). This impairment of fearmemory consolida-
tion by Nk3R antagonism is consistent with previous reports
where Nk3R activation with senktide in the hippocampus
and cortex leads to enhanced postsynaptic depolarization and
long-term potentiation (LTP) in slice physiology studies, and
this effect was blocked by NK3R antagonism (Gallopin et al.,
2006; Rekling, 2004). However, specific electrophysiological ex-
periments in the amygdala should be performed in the future to
study whether activation or blockade of the Nk3R in this struc-
ture is involved in LTP or other types of activity-dependent
plasticity.
In agreement with these prior findings, specific and temporal
pharmacogenetic silencing of Tac2-expressing neurons in the
CeA with DREADDs leads to impaired fear memory consolida-
tion. Of note, no effects in fear acquisition, pain sensitivity, or
anxiety-like behavior were detected when overexpressing
Tac2, inhibiting Tac2-expressing neurons, or with the Nk3R
antagonist, which is consistent with previous findings suggesting
that the Tac2-NkB-Nk3R pathway is not directly involved in
these processes, although it may modulate them (Ebner et al.,
2009; Mar et al., 2012; Siuciak et al., 2007). Interestingly, in our
fear paradigm, the Tac2 gene within the amygdala is involved
in auditory (CS+US paired) but not stress or contextual mem-
ories (US only). However, this does not preclude the hypothesis
that different fear paradigms might reveal a role of Tac2 in the
amygdala in contextual fear conditioning.
Thus, we believe that enhanced Tac2 gene expression in our
fear models enhanced NkB production in the amygdala, binding
to Nk3R and promoting fear memory consolidation. This upregu-
lation of Tac2 mRNA levels primarily within the CeM suggests
several possible nonmutually exclusive scenarios. The first is
that the Tac2 gene synthesizes NkB in the CeMamygdala, acting
on local Nk3R within the CeM specifically. The second is that
Tac2 mRNA and/or NkB are transported from the CeM to other
nuclei within the amygdala such as CeL, CeC, or BLA, where
they bind to the Nk3R. Our data also suggest that amygdala
cell culture with osanetant increases Nk3R mRNA levels. The
most likely interpretation is that osanetant antagonizes amyg-
dala Nk3R and due to its decreased availability, Nk3R mRNA is
increased to synthesize more Nk3R in a compensatory manner.
The current data provide intriguing support for a specific role of
Tac2 gene, via NkB activation of Nk3R in fear consolidation
within the CeA.
CeLon neurons essentially serve as disinhibitory cells for CeL-
off neurons. Both CeLon and CeLoff neurons release GABA
when activated. CeLon neurons send projections to CeLoff
neurons, and, therefore, the increased firing of CeLon neurons
during CS presentation results in inhibition of CeLoff neurons
(normally inhibiting the CeM) and, thus, in disinhibition of CeM,
promoting conditioned fear responses (Ciocchi et al., 2010).
Specifically, CeLoff neurons largely overlap with PKCd+ neurons
(Haubensak et al., 2010). Moreover, we also show that Tac2
gene is not colocalized with Enk in the CeM. Enk is colocalized
with PKCd in the CeL (Haubensak et al., 2010) and specific
CeA-Enk deletion decreases fear expression during FC withoutNeuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc. 449
Figure 5. Tac2 Overexpression in the Central Amygdala Is Sufficient to Enhance Fear Memory Consolidation and It Is Blocked by an Nk3R
Antagonist
(A) The lentivirus GFP-FUGW induces GFP expression but not Neurokinin B (NkB) in Hek293 cells. Scale bar, 10 mm.
(B) The lentivirus Tac2-FUGW induces NkB expression in Hek293 cells. DAPI staining (blue) indicates the cellular nuclei. NkB staining (red) is contrasted with GFP
fluorescence (green).
(C) Tac2-FUGW or GFP-FUGW was bilaterally infused in the central amygdala and mice were left undisturbed for 14 days.
(D) The lentivius Tac2-FUGW showing GFP expression in the CeA neurons infected with virus. Scale bar, 250 mm.
(E) Lentivirus Tac2-FUGW expression causes a 42% overexpression of Tac2 in the central amygdala. ***p % 0.001 versus LV-GFP. n = 9–15 per
group.
(F) Timeline of the experiment.
(legend continued on next page)
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Figure 6. Inducible Silencing of Tac2-
Expressing Neurons in the CeA with
Gi-DREADD Decreases Conditioned Fear
(A) Design of hM4Di-mCherry AAV and Tac2-Cre
mice.
(B) Tac2-Cre- or Tac2-Cre+ mice were infected
with the hM4Di-mCherry AAV in the CeA.
(C) The Gi receptor was inserted only on the Tac2-
CrecellsofTac2-Cre+miceasshownwithmCherry
expression from infected CeA; CeM, centromedial
amygdala; CeL, centrolateral amygdala; BLA,
basolateral amygdala. Scale bar, 125 mm.
(D) CNO was given systemically 30 min prior to
fear conditioning to Tac2-Cre-/hM4Di-mCherry
and Tac2-Cre+/hM4Di-mCherry mice. Temporal
silencing of the Tac2-expressing neurons in the
Tac2-Cre+/hM4Di-mCherry group did not affect
freezing during fear acquisition. However, when
mice were tested the day after for fear expression,
without CNO, Tac2-Cre+/hM4Di-mCherry mice
showed less conditioned fear. *p % 0.05 Tac2-
Cre-/hM4Di-mCherry versus Tac2-Cre+/hM4Di-
mCherry, n = 10–11 per group.
(E) Tac2-Cre-/hM4Di-mCherry and Tac2-Cre+/
hM4Di-mCherry mice were retrained to a different
acoustic tone (CS) without receiving CNO. Both
groups equally acquired fear learning and showed
similar levels of fear memory consolidation.
(F) CNO given 30 min before the elevated plus
maze showed no effect on Tac2-Cre-/hM4Di-
mCherry or Tac2-Cre+/hM4Di-mCherry in anxi-
ety-like behavior. See also Figure S6.
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the Tac2-CeM neuronal population appears to be independent
of, and complementary to, other previously described neuronal
populations involved in FC. The GAD65 peptide, abundantly
found at nerve terminals and synapses, plays a key role in
GABA neurotransmission (Pinal and Tobin, 1998). Additionally,
CaMKII is a well-known marker for synaptic plasticity. Thus,
the colocalization of Tac2mRNA levels andGAD65 and CaMKIIa
peptides in the CeM suggest that Tac2 gene may have a role in(G) Tac2 overexpression in the central amygdala does not alter anxiety-like behavior evaluated by the time
n = 9–15.
(H) Left: the lentiviruses GFP-FUGW and Tac2-FUGW cause no changes in fear conditioning. Osanetant or ve
acquisition. Right: Tac2 overexpression enhances fear memory consolidation (LV-Tac2-Veh) and osanetant im
*p% 0.05 versus LV-GFP-Veh, **p% 0.01 versus all other groups. Mean + or ± SEM is shown. See also Fig
Neuron 83, 444–neurotransmission within the GAD65 and
CaMKIIa-expressing neurons, in agree-
ment with our data that suggest that this
CeMpopulationmay be critically involved
in fear memory consolidation.
Finally, one of the most interesting as-
pects of our data is the potential use of
the Nk3R antagonist osanetant as a phar-
macological agent to block fear memory
consolidation shortly after exposure to a
trauma. Additionally, we found that osa-
netant prevented the upregulation of theAdcyap1r1 gene, which encodes the PAC1 receptor. The PA-
CAP-PAC1R pathway is involved in PTSD, fear conditioning,
amygdala excitatory neurotransmission, and stress (Almli et al.,
2013; Cho et al., 2012; Hashimoto et al., 2011; Ressler et al.,
2011; Uddin et al., 2013). All this could be relevant in PTSD pre-
vention since it has previously been found that osanetant is safe
in humans, although additional preclinical studies, such as those
described herein, are needed first to establish the mechanisms
involved. This gives our findings an exciting potential approachspent in the open arms in the elevated plus maze.
hicle were given systemically immediately after fear
pairs this effect (LV-Tac2-Osa). n = 3–8 per group.
ure S5.
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ways have previously been associated with PTSD, we believe
that there will be a number of different mechanisms identified
that eventually will synergistically be used to target emotional
memory modulation.
In summary, these studies provide understanding of the role of
the Tac2 gene and the CeM in fear processing and provide
approaches to intervention for fear-related disorders.
EXPERIMENTAL PROCEDURES
Procedures are described in detail in Supplemental Experimental Procedures.
Mice
Amygdala cell culture experiments were performed with male wild-type (WT)
C57BL/6J p21 mice. All other experiments were performed on adult WT
C57BL/6J or B6.129-Tac2tm1.1(cre)Qima/J (Tac2-Cre) (Mar et al., 2012)
from Jackson Laboratory (Stock 018938), male mice that were group-housed
in a temperature-controlled vivarium, with ad libitum access to food and water.
Animals were maintained on a 12 hr/12 hr light/dark cycle, with all behavioral
procedures being performed during the light cycle. All procedures used
were approved by the Institutional Animal Care and Use Committee of Emory
University and in compliance with National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals.
Immobilization to Wooden Board
Mice were exposed once for 2 hr to IMO, which was performed as previously
described (Andero et al., 2011, 2013).
mRNA Extraction and Microarray
Total mRNA was isolated and purified from the tissue with the RNeasy Mini Kit
(catalog 74106, QIAGEN). Illumina MouseWG-6 v2 Expression BeadChip
microarray (Illumina) was assayed for 45,281 transcripts as previously
described (Andero et al., 2013). FDR was calculated with SAM 4.01 using a
5% cutoff for the FDR rate. The heat maps were created with Genesis 1.4.0
(Sturn et al., 2002). The pathway analysis was generated through the use of
IPA (Ingenuity Systems, http://www.ingenuity.com). The microarray data are
publicly available in the Gene Expression Omnibus database under accession
number GSE57465.
Behavioral Experiments
Elevated plus-maze, open-field, cued-fear conditioning, and fear expression
tests were performed as previously described (Andero et al., 2011, 2013).
The CS was 30 s 0.6 kHz tone and the US was 1 mA 500 ms electric foot-
shocks. Retraining of mice was performed with a 12 kHz tone.
Complementary DNA Synthesis and qPCR
Total mRNA was reverse transcribed with the RT2 First Strand Kit (catalog
330401, QIAGEN). The primers used for the qPCR were TaqMan
Tac2 Mm01160362_m1, ADCYAP1R1 Mm01326453_m1, and NK3R
Mm00445346_m1 from Applied Biosystems. The qPCR was performed and
analyzed as previously described (Andero et al., 2013).
Radioactive In Situ Hybridization
Tissue was fixed in 4% paraformaldehyde, pretreated, and hybridized with
36SUTP-labeled cRNA riboprobes prepared from linearized constructs for
antisense sequence of Tac2 (T7 RNA polymerase) as previously described
(Rattiner et al., 2004).
Fluorescent In Situ Hybridization
cRNA riboprobes were prepared from linearized constructs for antisense se-
quences of Tac2, PKCd, and Enkephalin (T7 RNA polymerase) as previously
described (Jasnow et al., 2013). The Tac2 riboprobe was labeled with fluores-
cein and the PKCd and Enkephalin with digoxigenin. Signals were amplified
with the TSA Plus Fluorescein Fluorescence System or TSA Plus Cy5 Fluores-452 Neuron 83, 444–454, July 16, 2014 ª2014 Elsevier Inc.cence System (PerkinElmer) following each series of primary antibodies. Sec-
tions were then stained with DAPI (1:1,000), washed, and coverslipped with
Mowiol mounting medium (Jasnow et al., 2013).
Amygdala Cell Culture
Amygdala primary cell culture was performed as previously described (Mou
et al., 2011).
Immunohistochemistry
Pep2/ProNkB, IS-39 ab (1:500) was the antibody used to detect NkB. The
procedure was followed as previously described (Kallo´ et al., 2012). The pro-
cedure for detecting Gad65 (AB5082, Chemicon, 1:500) and CaMkIIa (Cell
Signaling Solutions, 1:250) was similar as previously described (Jasnow
et al., 2013) after performing the Tac2 FISH. After the ISH and IHC sections
were stained with DAPI (1:1,000), they were washed and coverslipped with
Mowiol mounting medium.
Immunocytochemistry
Immunocytochemistry was performed as previously described (Mou et al.,
2011). The antibody used was Pep2/ProNkB IHC (IS-39 ab, 1:500) (Kallo´
et al., 2012) and DAPI or NeuN (1:1,000).
ELISA
The mouse Neurokinin B ELISA kit was purchased from Mybiosource (Cata-
logue MBS744693). The inter-assay coefficient of variation is 7.5%–8.6%,
the intra-assay coefficient of variation is 8.2%–9.5% and the spike recovery
is 95%–103%. Procedure was followed as indicated by the manufacturer.
Production of Recombinant Viral Vectors
Mixture for transfection was 250 ug of FUGW or FUW-Tac2 + 187.5 ug of
pCMVdelta 8.9 + 75 ug of pV-SVG + 12 ml of ddH2O + 12.5 ml of 0.5M
Ca2Cl + 25 ml of 23 HeBS to total volume 50 ml; this solution was vortexed
a few seconds and incubated for 20 min at room temperature. Procedure
was followed as previously described (Huang et al., 2013). The pAAV-hSyn-
double floxed hM4D-mCherry (hM4Di-mCherry AAV) was purchased from
UNC Gene Therapy Center.
Surgery and Injection of Virus
Mice were anesthetized and placed in a stereotaxic frame. CeA coordinates
were as follows: anteroposterior, 1.34 mm; dorsoventral, 4.4 mm; medio-
lateral,2.4 mm relative to bregma. For the LV-Tac2 experiments, the animals
received bilateral intra-CeA amygdala injections of lentiviral vectors express-
ing Tac2-FUW or FUGW (GFP) in 1% BSA in PBS, 0.5 ml of virus/side. We
injected 1 ml of virus/side of the pAAV-hSyn-double floxed hM4D-mCherry
(hM4Di-mCherry AAV) in the CeA of Tac2-Cre- and Tac2-Cre+ mice. For all
experiments, the rate of injection was 0.1 ml/min and the needle was left in
place for 10 min after injection and the skin was closed using a 6-0 Vicryl
suture.
Drug Administration
The Nk3R antagonist osanetant (Axon Medchem, Axon 1533) was dissolved in
physiological saline and 0.1% Tween 20, which was also the vehicle. Intraper-
itoneal (i.p.) dose was 5 mg/kg for systemic administration and 0.5 ml with
625 ng dose per side for the intra-CeA studies. Cannulation of the mice was
performed as previously described (Andero et al., 2013). Clozapine-N-oxide
(CNO, Sigma Aldrich C0832) was given i.p. at 1 mg/kg (Krashes et al., 2011).
Statistics
Statistics were performed with IBM SPSS Statistics 19.0. Detection of outliers
was performed and, when necessary, removed from analyses. ANOVA
followed by post hoc analyses were appropriate, repeated-measures
ANOVA, or Student’s t test (two-tailed) for independent samples was tested.
The results are presented as means ± or + SEM, and statistical significance
was set at p% 0.05.
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The GEO accession number for the microarray data reported in this paper is
GSE57465.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2014.05.028.
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